Impaired redox signaling in Huntington’s disease: Therapeutic implications

Research output: Contribution to journalShort surveypeer-review

14 Scopus citations


Huntington’s disease (HD) is a neurodegenerative disease triggered by expansion of polyglutamine repeats in the protein huntingtin. Mutant huntingtin (mHtt) aggregates and elicits toxicity by multiple mechanisms which range from dysregulated transcription to disturbances in several metabolic pathways in both the brain and peripheral tissues. Hallmarks of HD include elevated oxidative stress and imbalanced redox signaling. Disruption of antioxidant defense mechanisms, involving antioxidant molecules and enzymes involved in scavenging or reversing oxidative damage, have been linked to the pathophysiology of HD. In addition, mitochondrial function is compromised in HD leading to impaired bioenergetics and elevated production of free radicals in cells. However, the exact mechanisms linking redox imbalance to neurodegeneration are still elusive. This review will focus on the current understanding of aberrant redox homeostasis in HD and potential therapeutic interventions.

Original languageEnglish (US)
Article number68
JournalFrontiers in Molecular Neuroscience
StatePublished - Feb 12 2019


  • Cysteine
  • Huntington’s disease
  • Mitochondria
  • Oxidative stress
  • Redox signaling

ASJC Scopus subject areas

  • Molecular Biology
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Impaired redox signaling in Huntington’s disease: Therapeutic implications'. Together they form a unique fingerprint.

Cite this